[Phase II study of 5'-DFUR in gastrointestinal and breast cancer].

Abstract

Clinical effects of daily oral administration of 5'-DFUR were studied in patients with advanced or recurrent gastrointestinal cancer and breast cancer. Cases included 5 gastric cancer, 18 colorectal cancer, 27 breast cancer and 1 malignant melanoma. Out of 38 cases who completed the treatment, CR was observed in 2 and PR in 7, the response rate being 23.7%. Out of 23 cases with breast cancer who completed the treatment, CR was observed in 2 and PR in 6, the response rate being 34.8%. Safety was evaluated in 42 cases and diarrhea was found in 17.1% of cases; however, it was easily reduced by decreasing the dosage or discontinuing administration of the drug.

• Authors: T Tominaga, M Kitamura, K Hayashi, I Takahashi, G Kosaki
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 12 Issue 11 Pg. 2172-8 (Nov 1985) ISSN: 0385-0684 [Print] Japan
• PMID: 2933000 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Antineoplastic Agents
• Floxuridine
• doxifluridine

Topics

• Administration, Oral
• Adult
• Aged
• Antineoplastic Agents (adverse effects, therapeutic use)
• Breast Neoplasms (drug therapy)
• Colonic Neoplasms (drug therapy)
• Diarrhea (chemically induced)
• Drug Administration Schedule
• Drug Evaluation
• Female
• Floxuridine (adverse effects, therapeutic use)
• Humans
• Leukopenia (chemically induced)
• Lymphatic Metastasis
• Male
• Melanoma (drug therapy)
• Middle Aged
• Nausea (chemically induced)
• Rectal Neoplasms (drug therapy)
• Stomach Neoplasms (drug therapy)